TP53: Coordinator of the Processes That Underlie the Hallmarks of Cancer

In 2000, Hanahan and Weinberg proposed that the remarkable diversity of neoplastic diseases and of their underlying molecular mechanisms could be rationalized into six biological processes that, together, constitute the molecular and cellular infrastructure of cancer, thus identifying the “Hallmarks of Cancer” (Hanahan and Weinberg, Cell 100: 57–70, 2000). To the six initial Hallmark processes (sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis), advances in the past decade have added four biological processes, including genome instability, tumor-promoting inflammation, reprogramming of cell bioenergetics, and evading immune destruction. Far from constituting independent biological programs, the Hallmark processes are redundant and deeply interconnected. The p53 protein, encoded by the TP53 tumor suppressor gene, has an exceptionally diverse range of biological functions that endows it with the capability to contribute to each of the ten Hallmark processes. In this overview, I illustrate how p53 may participate in each of these processes and I propose that its unique tumor suppressive properties stem from its capacity to coordinate them into a coherent set of responses. This point of view supports the idea that combining p53-targeted intervention with drugs targeting specific Hallmark capabilities may provide a principle for a form of next-generation adjuvant therapy enhancing and extending the clinical benefits of emerging new anticancer drugs.

[1]  S. Kyo,et al.  Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  P. Bénit,et al.  AIF deficiency compromises oxidative phosphorylation , 2004, The EMBO journal.

[3]  David Beach,et al.  Glycolytic enzymes can modulate cellular life span. , 2005, Cancer research.

[4]  P. Hainaut,et al.  Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma , 2008, Molecular carcinogenesis.

[5]  A. Levine,et al.  Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function , 2010, Proceedings of the National Academy of Sciences.

[6]  A. Mes-Masson,et al.  p53 inhibits angiogenesis by inducing the production of Arresten. , 2012, Cancer research.

[7]  E. Morselli,et al.  Defective autophagy control by the p53 rheostat in cancer , 2010, Cell cycle.

[8]  A. McClatchey,et al.  Nf2/Merlin: a coordinator of receptor signalling and intercellular contact , 2007, British Journal of Cancer.

[9]  V. de Laurenzi,et al.  p63/p73 in the control of cell cycle and cell death. , 2012, Experimental cell research.

[10]  U. Moll,et al.  The transcription-independent mitochondrial p53 program is a major contributor to Nutlin-induced apoptosis in tumor cells , 2009, Cell cycle.

[11]  C. Harris,et al.  Up-regulation of inducible nitric oxide synthase expression in cancer-prone p53 knockout mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Gerard I. Evan,et al.  Modeling the Therapeutic Efficacy of p53 Restoration in Tumors , 2006, Cell.

[13]  K. Ryan,et al.  DRAM Links Autophagy to p53 and Programmed Cell Death , 2007, Autophagy.

[14]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[15]  Y. Zou,et al.  XPA-Mediated Regulation of Global Nucleotide Excision Repair by ATR Is p53-Dependent and Occurs Primarily in S-Phase , 2011, PloS one.

[16]  K. Vousden,et al.  Role of NF-κB in p53-mediated programmed cell death , 2000, Nature.

[17]  M. Blasco,et al.  A p53-Dependent Response Limits Epidermal Stem Cell Functionality and Organismal Size in Mice with Short Telomeres , 2009, PloS one.

[18]  V. Rotter,et al.  Structural and functional involvement of p53 in BER in vitro and in vivo , 2001, Oncogene.

[19]  Yusuke Nakamura,et al.  Identification of ALDH4 as a p53-inducible gene and its protective role in cellular stresses , 2004, Journal of Human Genetics.

[20]  Michael K. Wendt,et al.  Mechanisms of the epithelial-mesenchymal transition by TGF-beta. , 2009, Future oncology.

[21]  Zhaohui Feng,et al.  p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment. , 2010, Cold Spring Harbor perspectives in biology.

[22]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[23]  B. Walker,et al.  From sentencing to execution – the processes of apoptosis , 2010, The Journal of pharmacy and pharmacology.

[24]  L. Chin,et al.  Telomere dysfunction induces metabolic and mitochondrial compromise , 2011, Nature.

[25]  E. Morselli,et al.  Stimulation of autophagy by the p53 target gene Sestrin2 , 2009, Cell cycle.

[26]  Pierre Hainaut,et al.  Massively regulated genes: the example of TP53 , 2010, The Journal of pathology.

[27]  T. Brabletz MiR-34 and SNAIL: Another double-negative feedback loop controlling cellular plasticity/EMT governed by p53 , 2012, Cell cycle.

[28]  S. Velasco-Miguel,et al.  Induction of the growth inhibitor IGF-binding protein 3 by p53 , 1995, Nature.

[29]  Michael R. Green,et al.  p53-Mediated Inhibition of Angiogenesis Through Up-Regulation of a Collagen Prolyl Hydroxylase , 2006, Science.

[30]  J. Marine,et al.  Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice , 2008, Cell Death and Differentiation.

[31]  M. Oren,et al.  New plays in the p53 theater. , 2011, Current opinion in genetics & development.

[32]  Angel Porgador,et al.  Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. , 2011, Cancer research.

[33]  Pierre Hainaut,et al.  Next-generation sequencing: emerging lessons on the origins of human cancer , 2011, Current opinion in oncology.

[34]  B. Seliger,et al.  Upregulation of Major Histocompatibility Complex Class I on Liver Cells by Hepatitis C Virus Core Protein via p53 and TAP1 Impairs Natural Killer Cell Cytotoxicity , 2003, Journal of Virology.

[35]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[36]  Samy Lamouille,et al.  TGF-β-induced epithelial to mesenchymal transition , 2009, Cell Research.

[37]  L. Wiesmüller,et al.  p53 in recombination and repair , 2006, Cell Death and Differentiation.

[38]  Tim Crook,et al.  Functional regulation of p73 and p63: development and cancer. , 2003, Trends in biochemical sciences.

[39]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[40]  R. Abraham,et al.  The autophagy conundrum in cancer: influence of tumorigenic metabolic reprogramming , 2011, Oncogene.

[41]  M. Olivier,et al.  Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome , 2010, Current opinion in oncology.

[42]  Eyal Gottlieb,et al.  TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis , 2006, Cell.

[43]  W. El-Deiry,et al.  The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth, and chemosensitivity under hypoxic conditions , 2009, Cell cycle.

[44]  D. Menendez,et al.  The Toll-Like Receptor Gene Family Is Integrated into Human DNA Damage and p53 Networks , 2011, PLoS genetics.

[45]  B. Kaina,et al.  p53 is involved in regulation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents , 1998, Oncogene.

[46]  Hongtae Kim,et al.  Merlin Neutralizes the Inhibitory Effect of Mdm2 on p53* , 2004, Journal of Biological Chemistry.

[47]  R. Baxter,et al.  The IGF axis and programmed cell death , 1999, Immunology and cell biology.

[48]  D. Trinh,et al.  Direct interaction between p53 and Tid1 proteins affects p53 mitochondrial localization and apoptosis , 2010, Oncotarget.

[49]  Robert S. Balaban,et al.  p53 Improves Aerobic Exercise Capacity and Augments Skeletal Muscle Mitochondrial DNA Content , 2009, Circulation research.

[50]  M. Armoni,et al.  The Tumor Suppressor p53 Down-Regulates Glucose Transporters GLUT1 and GLUT4 Gene Expression , 2004, Cancer Research.

[51]  p53 regulates epithelial-mesenchymal transition (EMT) and stem cell properties through modulating miRNAs , 2010, Nature Cell Biology.

[52]  M. Oren,et al.  Wild-type p53 can inhibit oncogene-mediated focus formation. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[53]  A. Børresen-Dale,et al.  TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes , 2007, Oncogene.

[54]  B. Vojtesek,et al.  The role of P63 in cancer, stem cells and cancer stem cells , 2011, Cellular & Molecular Biology Letters.

[55]  P. Hainaut,et al.  Redox control and interplay between p53 isoforms: roles in the regulation of basal p53 levels, cell fate, and senescence. , 2011, Antioxidants & redox signaling.

[56]  V. Rotter,et al.  Mutant p53R175H upregulates Twist1 expression and promotes epithelial–mesenchymal transition in immortalized prostate cells , 2011, Cell Death and Differentiation.

[57]  P. Hainaut,et al.  Roles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity , 2005, Oncogene.

[58]  S. Weitzman,et al.  Chronic inflammation and cancer: the role of the mitochondria. , 2011, Oncology.

[59]  D. Schadendorf,et al.  Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. , 2012, Cancer research.

[60]  D. Trinh,et al.  Tid1 is a new regulator of p53 mitochondrial translocation and apoptosis in cancer , 2010, Oncogene.

[61]  Uri Tabori,et al.  Excessive genomic DNA copy number variation in the Li–Fraumeni cancer predisposition syndrome , 2008, Proceedings of the National Academy of Sciences.

[62]  L. Donehower,et al.  The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair. , 2004, Molecular cell.

[63]  R. Maestro,et al.  Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. , 2008, Cancer cell.

[64]  Ronald A. DePinho,et al.  Linking functional decline of telomeres, mitochondria and stem cells during ageing , 2010, Nature.

[65]  S. Sommer,et al.  Most spontaneous tumors in a mouse model of Li-Fraumeni syndrome do not have a mutator phenotype. , 2006, Carcinogenesis.

[66]  Y. Zou,et al.  Differential DNA damage responses in p53 proficient and deficient cells: cisplatin-induced nuclear import of XPA is independent of ATR checkpoint in p53-deficient lung cancer cells. , 2011, International journal of biochemistry and molecular biology.

[67]  D. Lyden,et al.  The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. , 2011, Seminars in cancer biology.

[68]  D. Trinh,et al.  Direct interaction between p53 and Tid1 proteins affects p53 mitochondrial localization and apoptosisy as a Target for Cancer Therapy , 2010 .

[69]  David Lane,et al.  p53 Research: the past thirty years and the next thirty years. , 2010, Cold Spring Harbor perspectives in biology.

[70]  Sam W. Lee,et al.  p53 Serves as a Host Antiviral Factor That Enhances Innate and Adaptive Immune Responses to Influenza A Virus , 2011, The Journal of Immunology.

[71]  B. Goud,et al.  TSAP6 Facilitates the Secretion of Translationally Controlled Tumor Protein/Histamine-releasing Factor via a Nonclassical Pathway* , 2004, Journal of Biological Chemistry.

[72]  M. Weller,et al.  Synthesis of cytochrome c oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death , 2012, Oncogene.

[73]  E. Abraham,et al.  p53 Attenuates Lipopolysaccharide-Induced NF-κB Activation and Acute Lung Injury 1 , 2009, The Journal of Immunology.

[74]  M. Swaroop,et al.  Transcriptional Activation of the Human Glutathione Peroxidase Promoter by p53* , 1999, The Journal of Biological Chemistry.

[75]  P. Hainaut,et al.  30 years and a long way into p53 research. , 2009, The Lancet. Oncology.

[76]  Nobuyuki Tanaka,et al.  p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation , 2008, Nature Cell Biology.

[77]  V. Rotter,et al.  Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells , 2010, The Journal of experimental medicine.

[78]  Kyu-Won Kim,et al.  Hypoxia-induced angiogenesis during carcinogenesis. , 2003, Journal of biochemistry and molecular biology.

[79]  M. Blasco,et al.  p53 Prevents Entry into Mitosis with Uncapped Telomeres , 2010, Current Biology.

[80]  B. Kopnin,et al.  p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway. , 2009, Cancer letters.

[81]  A. Levine,et al.  Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway , 2012, Cell.

[82]  L. Donehower,et al.  Homeostatic Regulation of Base Excision Repair by a p53-Induced Phosphatase: Linking Stress Response Pathways with DNA Repair Proteins , 2004, Cell cycle.

[83]  Qing Gao,et al.  Endogenous LKB1 knockdown accelerates G1/S transition through p53 and p16 pathways , 2010, Cancer biology & therapy.

[84]  P. Raychaudhuri,et al.  Tumor suppression by ARF: Gatekeeper and caretaker , 2010, Cell cycle.

[85]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[86]  Carlos Cordon-Cardo,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.

[87]  M. Oren,et al.  Decision making by p53: life, death and cancer , 2003, Cell Death and Differentiation.

[88]  J. Shay,et al.  Telomeres and Telomerase: Implications for Cancer and Aging , 2001, Radiation research.

[89]  Samy Lamouille,et al.  Oncogene and tumour suppressor: the two faces of SnoN , 2009, EMBO Journal.

[90]  J. Zhuang,et al.  p53: exercise capacity and metabolism , 2012, Current opinion in oncology.

[91]  Kevin M. Ryan,et al.  DRAM, a p53-Induced Modulator of Autophagy, Is Critical for Apoptosis , 2006, Cell.

[92]  M. Olivier,et al.  Biological functions of p53 isoforms through evolution: lessons from animal and cellular models , 2011, Cell Death and Differentiation.

[93]  W P Bennett,et al.  Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. , 1999, Journal of the National Cancer Institute.

[94]  K. Helin,et al.  Suppression of the p53- or pRB-mediated G1 checkpoint is required for E2F-induced S-phase entry , 2002, Nature Genetics.

[95]  Y. Yin,et al.  PTEN: a new guardian of the genome , 2008, Oncogene.

[96]  E. Gottlieb,et al.  p53 regulation of metabolic pathways. , 2010, Cold Spring Harbor perspectives in biology.

[97]  Lixin Wei,et al.  Epithelial-Mesenchymal Transition in tumor microenvironment , 2011, Cell & Bioscience.

[98]  D. Andrews,et al.  BH3-only proteins: Orchestrators of apoptosis. , 2011, Biochimica et biophysica acta.

[99]  C. Harris,et al.  Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[100]  A. Chatterjee,et al.  The effect of p53‐RNAi and p53 knockout on human 8‐oxoguanine DNA glycosylase (hOgg1) activity , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[101]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[102]  P. Hainaut,et al.  Cross‐talks between cyclooxygenase‐2 and tumor suppressor protein p53: Balancing life and death during inflammatory stress and carcinogenesis , 2007, International journal of cancer.

[103]  A. Mancuso,et al.  p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase , 2011, Nature Cell Biology.

[104]  W. El-Deiry,et al.  KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53-tumor suppressor to caspase activation and apoptotic death. , 2000, Advances in experimental medicine and biology.